Abstract To evaluate safety and tolerability of EYP-1901, an intravitreal insert containing vorolanib, a pan–vascular endothelial growth factor (VEGF) receptor inhibitor packaged in a bioerodible delivery technology (Durasert E™) for sustained delivery, in patients with wet age-related macular degeneration (wAMD) previously treated with anti-VEGF therapy. Phase 1, multicenter, prospective, open-label, dose-escalation trial. Patients with wAMD and evidence of prior anti-VEGF therapy response.
Philip Storey
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Get in touch with Philip
Contact Philip, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack